- Home
- BTOG vs NRSN Comparison
BTOG vs NRSN Comparison
Compare BTOG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTOG | NRSN |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 26.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BTOG | NRSN |
|---|---|---|
| Price | $0.17 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.0M | 335.2K |
| Earning Date | 03-30-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,495.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.12 | $0.76 |
| 52 Week High | $1.07 | $2.60 |
Technical Indicators
Market Signals| Indicator | BTOG | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 27.21 | 34.74 |
| Support Level | $0.21 | $0.76 |
| Resistance Level | $0.23 | $0.91 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 4.74 | 10.78 |
Price Performance
Historical ComparisonAbout BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.